RxDoctor Payments Data

Daniela Oneil

Family · Yardley, PANPI 1902267909

Payments from drug & device makers

$2,005in general payments, 2019–2025

Across 117 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$510
  • Lilly USA, LLC$326
  • AbbVie$255
  • Exact Sciences$163
  • Otsuka America Pharmaceutical, Inc.$116
  • AstraZeneca$96
  • plus $539 from 16 others

What the payments were for

  • Food & beverage$2,005100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,005 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$30,246
Medicare patients
78
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin13$48,426
OzempicSemaglutide40$38,919
WegovySemaglutide22$29,464
LinzessLinaclotide23$28,598
MounjaroTirzepatide20$24,870
Breo ElliptaFluticasone/Vilanterol37$17,386
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,348
EliquisApixaban19$13,272
VascepaIcosapent Ethyl12$3,920
Duloxetine Hcl22$2,961
ClomidClomiphene Citrate12$2,632
Dexlansoprazole DrDexlansoprazole11$2,043
Topiramate24$1,926
Albuterol Sulfate HfaAlbuterol Sulfate73$1,776
SynthroidLevothyroxine Sodium14$1,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$510$68,38462 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$18$48,42613 claims
GSKBreo Ellipta, Trelegy Ellipta$34$34,73564 claims
AbbVieLinzess, Synthroid$255$30,23837 claims
Lilly USA, LLCMounjaro$326$24,87020 claims
PfizerEliquis$72$13,27219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.

Other family in Yardley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →